Login / Signup

Cost-effectiveness of tofacitinib compared with infliximab, adalimumab, golimumab, vedolizumab and ustekinumab for the treatment of moderate to severe ulcerative colitis in Germany.

Aditya SardesaiAxel U DignassPeter QuonSandra MilevJoseph Christopher CappelleriAgnes KisserIrene ModestoPuza P Sharma
Published in: Journal of medical economics (2021)
The results of this economic model suggest tofacitinib is a cost-effective treatment option for patients with moderate to severe UC in Germany.
Keyphrases
  • ulcerative colitis
  • rheumatoid arthritis
  • drug induced
  • patients with inflammatory bowel disease